Combioxin Announces Completion of CAL02 FIM Trial in Patients with Severe Pneumococcal Pneumonia

March 29, 2018
Combioxin SA

29 March 2018 – Combioxin SA announced today the completion of the first-in-man CAL02-001 clinical study ( This was a randomized, multicentre,double-blind, placebo-controlled study designed to assess the safety and tolerability of CAL02 in severe community-acquired pneumonia due to Streptococcus pneumoniae as well as exploring efficacy and pharmacodynamics parameters. This study included two CAL02 dosing regimens. An Independent Data Monitoring Committee unanimously supported a positive safety profile of CAL02 at both regimens.

Press release available here: